CA3237737A1 - Compositions de cannabinoides et d'acides gras omega et leurs methodes d'utilisation - Google Patents

Compositions de cannabinoides et d'acides gras omega et leurs methodes d'utilisation Download PDF

Info

Publication number
CA3237737A1
CA3237737A1 CA3237737A CA3237737A CA3237737A1 CA 3237737 A1 CA3237737 A1 CA 3237737A1 CA 3237737 A CA3237737 A CA 3237737A CA 3237737 A CA3237737 A CA 3237737A CA 3237737 A1 CA3237737 A1 CA 3237737A1
Authority
CA
Canada
Prior art keywords
cbda
cbd
omega
cannabinoid
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3237737A
Other languages
English (en)
Inventor
Elliot Altman
Matthew Fuller
Gheda ALSAIF
Shannon Smith
Karen MAYNARD
Anthony FARONE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Greenway Herbal Products LLC
Original Assignee
Greenway Herbal Products LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/931,249 external-priority patent/US20230015268A1/en
Application filed by Greenway Herbal Products LLC filed Critical Greenway Herbal Products LLC
Priority claimed from US18/164,044 external-priority patent/US20230248747A1/en
Publication of CA3237737A1 publication Critical patent/CA3237737A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente divulgation concerne des compositions comprenant des cannabinoïdes et des acides gras oméga et des méthodes d'utilisation de ces compositions notamment, par exemple, pour traiter ou prévenir une inflammation, en tant qu'immunosuppresseur et/ou en tant qu'agent thérapeutique anticancéreux. Selon certains aspects, le cannabinoïde est choisi parmi i) CBC, CBCA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBL, CBLA, CBN, CBNA, THCV, THCVA et toute combinaison de ceux-ci, et ii) un mélange de CBD:CBDA équimolaire d'environ 1:1. Dans certains aspects, l'acide gras oméga est choisi parmi un acide gras oméga-3 (tel que ALA, DHA ou EPA), un acide gras oméga-7, ou un acide gras oméga-9.
CA3237737A 2022-09-12 2023-02-03 Compositions de cannabinoides et d'acides gras omega et leurs methodes d'utilisation Pending CA3237737A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17/931,249 2022-09-12
US17/931,249 US20230015268A1 (en) 2019-04-30 2022-09-12 Cannabinoid and omega fatty acid compositions and methods of using
US18/164,044 2023-02-03
US18/164,044 US20230248747A1 (en) 2019-04-30 2023-02-03 Cannabinoid and omega fatty acid compositions and methods of using
PCT/US2023/061944 WO2024059353A1 (fr) 2022-09-12 2023-02-03 Compositions de cannabinoïdes et d'acides gras oméga et leurs méthodes d'utilisation

Publications (1)

Publication Number Publication Date
CA3237737A1 true CA3237737A1 (fr) 2024-03-21

Family

ID=90275771

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3237737A Pending CA3237737A1 (fr) 2022-09-12 2023-02-03 Compositions de cannabinoides et d'acides gras omega et leurs methodes d'utilisation

Country Status (3)

Country Link
CA (1) CA3237737A1 (fr)
GB (1) GB2629099A (fr)
WO (1) WO2024059353A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315621A (en) * 2024-09-12 2026-04-01 Imi Tami Institute For Res And Development Ltd Gonadotropin esters of cannabinoids, methods of their preparation, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US20190374502A1 (en) * 2017-02-09 2019-12-12 Bodhi Research & Development Inc. Cannabinoid-Containing Fatty Acid Formulations for Treating Disorders of the Nervous System
US20190336471A1 (en) * 2018-05-02 2019-11-07 Omax Health Compositions containing omega-3 fatty acids concentrates, cannabanoids and l-theanine and use thereof
WO2020223510A1 (fr) * 2019-04-30 2020-11-05 Greenway Herbal Products, Llc Compositions de cannabinoïdes et procédés d'utilisation

Also Published As

Publication number Publication date
GB202409642D0 (en) 2024-08-14
GB2629099A (en) 2024-10-16
WO2024059353A1 (fr) 2024-03-21

Similar Documents

Publication Publication Date Title
US20260000687A1 (en) Cannabinoid compositions and methods of using
US20230248747A1 (en) Cannabinoid and omega fatty acid compositions and methods of using
US20230015268A1 (en) Cannabinoid and omega fatty acid compositions and methods of using
US20080234362A1 (en) Treatment for Asthma and Arthritis and Other Inflammatory Diseases
JP6378694B2 (ja) 固溶体組成物および激痛における使用
US9295682B2 (en) Adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of clinical manifestations associated with diseases like cachexia and correction of adverse effects of drugs such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier specially selected and other substances with antineoplastic action and/or other treatments
Jakhar et al. Morin hydrate augments phagocytosis mechanism and inhibits LPS induced autophagic signaling in murine macrophage
Gambari et al. Overview of anti-inflammatory and anti-nociceptive effects of polyphenols to halt osteoarthritis: from preclinical studies to new clinical insights
CA3158390A1 (fr) Formulation combinant un cannabinoide et un precurseur de nad+ pour le traitement d'une inflammation et procedes associes
CA3105082A1 (fr) Compositions d'associations de cannabidiol
CA3237737A1 (fr) Compositions de cannabinoides et d'acides gras omega et leurs methodes d'utilisation
US20230302026A1 (en) Immunomodulation formulations and related methods
EP4419108A1 (fr) Compositions de cannabinoïdes et d'acides gras oméga et leurs méthodes d'utilisation
CA2986371C (fr) Combinaison comprenant du palmitoylethanolamide (pea) et du e lycopene pour utilisation dans le traitement de maladies inflammatoires
KR101928553B1 (ko) 진세노사이드 화합물을 함유하는 인플라마좀 매개 염증성 질환의 예방 또는 치료용 조성물
EA014070B1 (ru) Применение растительной композиции для лечения воспалительных нарушений
US9545419B1 (en) Method and compositions for treating chronic inflammatory disorders
Oliveira et al. Simvastatin attenuated sickness behavior and fever in a murine model of endotoxemia
US20200289431A1 (en) Combination of cannabidiol and nsaids for the treatment of sciatica and other nerve pain
US11426363B2 (en) Compositions including cannabis and avocado/soybean unsaponifiables and methods of use
CA3123524C (fr) Compositions nutritionnelles synergiques pour la gestion de la douleur
US10154974B1 (en) Use of abscisic acid for the prevention and treatment of malaria
Belenska-Todorova et al. IN VIVO ELUCIDATION OF ANTI-ARTHRITIC EFFECT OF PLANT ALKALOID BERERINE IN EXPERIMENTAL MOUSE JOINT INFLAMMATION
Dinc et al. Research Article An Assessment of the Chondroprotective Effects of Intra-Articular Application of Statin and Tetracycline on Early-Stage Experimental Osteoarthritis

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20241022

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241106

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241106

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250611

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20251009

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251120